Kornimate/medical-research-clean huggingface dataset:
exploring mechanisms and morphology of qt interval prolongation

Conditions: Long Qt Syndrome 1-2; Sudden Cardiac Death

Summary: the projects will try and optimise the risk stratification for patients with long qt syndrome by investigating how the exposure of physical and acoustic stress will affect the qt-dynamics and if beta blockers protect against arrhythmias by suppressing this dynamic qt-prolongation. furthermore, the project will investigate the effects of spironolactone on the qt-dynamics tested by "brisk standing". first, patients are tested with known arrhythmic triggers and they are then administered thier normal dose of beta blockers. hereafter, "brisk standing" test is performed and the patients are on spironolactone for seven days. after seven days treatment the "brisk standing" is repeated.

the aim of the projects is to try and optimise the risk stratification for patients with long qt syndrome by investigating how the exposure of physical and acoustic stress will affect the qt-dynamics and if beta blockers protect against arrhythmias by suppressing this dynamic qt-prolongation. furthermore, the project will investigate the effects of spironolactone on the qt-dynamics tested by "brisk standing". first, patients are tested with known arrhythmic triggers and they are then administered thier normal dose of beta blockers. hereafter, "brisk standing" test is performed and the patients are on spironolactone for seven days. after seven days treatment the "brisk standing" is repeated.

Eligibility criteria:
inclusion criteria: * verified long qt syndrome mutation, subtype 1 or 2. * over 18 years of age exclusion criteria: * atrioventricular block, * left bundle branch block, * left ventricular hypertrophy, * pace rhythm, * st-deviations \>1 mm), * left ventricular ejection fraction \<50 % and significant valvulopathy, * unstable psychiatric disease * unstable cardiovascular disease.

Keywords: long qt syndrome
efficacy and tolerability of zd6474 in patients with thyroid cancer

Conditions: Thyroid Cancer

Summary: the purpose of this open label, two stage, phase ii study is to evaluate the efficacy and tolerability of zd6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.


Eligibility criteria:
inclusion criteria: * locally advanced or hereditary medullary thyroid cancer * signed informed consent * one or more measurable lesions exclusion criteria: * brain metastases or spinal cord compression * specific laboratory ranges * specific heart problems * prior chemotherapy and/or radiation therapy * participation in other trials within 30 days

Keywords: caprelsa (vandetanib) zd6474
tissue kallikrein preventing the restenosis after stenting of symptomatic mca atherosclerotic stenosis

Conditions: Cerebrovascular Disease

Summary: the study aims to determine whether tissue kallikrein (tk) is efficacy for preventing the long-term in-stent restenosis (isr) after stenting of symptomatic atherosclerotic stenosis of the middle cerebral artery (mca) m1 segment

a series of studies have confirmed the kallikrein-kinin system (kks), including kallikrein, kininogen and kinin, plays an important role in the regulation of inflammation secondary to acute and chronic ischemic brain injury. some researchers found that htk gene delivery can inhibit the formation of neointimal induced by the common carotid artery ligation in mice. further study revealed htk gene transfection in vsmc lead to increased secretion of tk and inhibition of vsmc proliferation. in addition, it was also observed that the serum tk levels were coincident with the carotid artery stenosis. the more severe the stenosis is, the higher the serum tk level is, and the serum tk decreased after carotid artery angioplasty and stent placement. these results suggest that kks play an important regulatory role in vascular remodeling and tk may exert a beneficial influence in the process of isr

Eligibility criteria:
inclusion criteria: 1. tia or stroke in the mca territory refractory to aggressive anti-platelet and regular statin therapy in 3 months 2. symptomatic mca m1 segment stenosis ≥ 70% confirmed with dsa 3. successfully treated with ptas without acute surgical complications in 12 hours after operation 4. all patients provided fully informed consent exclusion criteria: 1. using angiotensin-converting enzyme inhibitors 2. severe cardiopulmonary dysfunction, chronic liver disease (a / g inversion, alt increased 2-fold greater than normal), abnormal renal function (serum creatinine greater than 1.5 times normal) 3. allergies, the history of allergy to multi-drug 4. the history of cerebral hemorrhage, brain tumors, brain trauma, cerebral embolism and other brain lesions 5. during pregnancy or breast-feeding 6. not expected to complete follow-up

Keywords: ischemic stroke; in-stent restenosis; tissue kallikrein; the middle cerebral artery; atherosclerotic stenosis
the effects of physical exercise training in patients with chronic obstructive pulmonary disease

Conditions: COPD; Exercise; Resistance Training

Summary: the purpose of the present project is to investigate the physiological effects of two different types of exercise training in copd patients. the patients will be examined before, during and after 8 weeks of training to evaluate the effect of different types of skeletal muscle stimulation on health related quality of life, 6 min walking distance, flow mediated dilation, and histological properties of skeletal muscle cells, regarding oxidative capacity, fiber type, purinergic receptor amounts and measures of systemic inflammation. the study will test the hypothesis that: resistance training is superior to endurance training in patients with copd


Eligibility criteria:
inclusion criteria: * fev1/fvc fixed ratio \ or equal to 3 * arterial oxygen saturation at rest\> 90%, bmi \>18, lvef\> 45. * age: 40 - 80 years the medical treatment will be continued unchanged during the study and additional prednisolone and /or antibiotic treatment will be prescribed in case of acute exacerbation. exclusion criteria: * unstable ischemic heart disease, severe heart valve failure, pulmonary emboli, severe heart failure, severe infections, musculoskeletal disorders, malignant disease, contraindicated medicine as mao inhibitors and anticoagulants.
the effects of a carotenoid intervention on cognitive function

Conditions: Mild Cognitive Impairment

Summary: past research suggests that retinal lutein levels are related to cognitive function as measured via behavioral tests. the goal of the present study is to investigate the relationship between lutein and cognitive function in a wider variety of the population (young, healthy adults and older adults), using a wider variety of methods (behavioral testing and neuroimaging).

past research suggests that retinal lutein levels are related to cognitive function as measured via behavioral tests. the goal of the present study is to investigate the relationship between lutein and cognitive function in a wider variety of the population (young, healthy adults and older adults), using a wider variety of methods (behavioral testing and neuroimaging).

Eligibility criteria:
inclusion criteria: * visual acuity correctable to 20:40 or better, snellen notation * able to swallow a dietary supplement * free of dementia, characterized by a score of less than 1.5 on the clinical dementia rating scale exclusion criteria: * gi conditions that interfere with lipid absorption * presence of or past diagnosis of age-related macular degeneration * visual acuity poorer than 20:40, snellen notation * has taken lutein, omega-3 fatty acid or fish oil supplements within the last 6 months * presence of dementia, characterized by a score of 1.5 or greater on the clinical dementia rating scale

Keywords: lutein cognition neural efficiency aging
effect of vitamin e+selenium on kidney function in controlled hypotension

Conditions: Acute Kidney Injury

Summary: the purpose of this study is to determine whether kidney injury happens in controlled hypotension during brain operations by using neutrophil gelatinase associated lipocalin elisa kit and if so, does vitamine+selenium prevent it

ngal(neutrophil gelatinase associated lipocalin) is a 25kd protein which bounds with gelatinase in neutrophil granules.it is also expressed in epithelial cells of kidney tubules.ngal increases in ischemic and toxic injuries of kidney. during controlled hypotension in brain operations injury to the kidneys might occur . this study is designed to assess this possibility and evaluate the effect of vitamine+selenium on prevention of this problem

Eligibility criteria:
inclusion criteria: * all patients who are candidate for brain surgery under controlled hypotension exclusion criteria: * positive history of renal disease * positive history of diabetes mellitus, chf, htn, breast cancer, fever, leukocytosis
effects of thyroidectomy on obstructive sleep apnea in patients suffering from goiters

Conditions: Goiter

Summary: literature regarding effects of goiter on the occurrence of obstructive sleep apnea (osa) remains scarce. reports have described cases of osa in patients suffering from goiters, resolved after thyroidectomy. it has been recently shown that goiters of a total volume exceeding 25 ml leads to \>30% tracheal compression. the aims of the present study is to assess 1) the prevalence of osa in patients suffering from goiters and planned for thyroidectomy 2) the role of thyroidectomy in osa resolution in patients suffering from pre-operative osa 3) the identification of predictors for persisting osa.

introduction literature regarding effects of goiter on the occurrence of obstructive sleep apnea (osa) remains scarce. reports have described cases of osa in patients suffering from goiters, resolved after thyroidectomy. it has been recently shown that goiters of a total volume exceeding 25 ml leads to \>30% tracheal compression. the aims of the present study is to assess 1) the prevalence of osa in patients suffering from goiters and planned for partial/total thyroidectomy 2) the role of thyroidectomy in osa resolution in patients suffering from pre-operative osa 3) the identification of predictors for persisting osa. methods design prospective study settings tertiary referral center, university hospital patients patients referred for partial/total thyroidectomy for goiter baseline assessment all patients planned for thyroidectomy will be prospectively included. exclusion criteria will be: previous cervical surgery/radiotherapy, language barrier, chest disease known to narrow upper airways. patient will be assessed by home polysomnography(psg), one night, pulmonary function tests, including respiratory muscle strength, and comprehensive biological assessment of thyroid function. follow up three months after thyroidectomy, the same assessment will be repeated. statistical analysis statistical analysis will be performed to determine the percentage of patients suffering from osa before surgery (apnea-hypopnea index (ahi) \>5/hour of sleep on psg). as the aim of the present study is to assess the role of thyroidectomy in osa resolution, we will compare pre- and post-thyroidectomy psg results in patients exhibiting ahi \>5/hour of sleep (chi square test). osa resolution will be defined as decrease in ahi \> 50 % or reduction of ahi \<5hour of sleep. as one of the secondary aim is the identification of predictors for persisting osa, multivariate analysis will be performed to assess factors of persisting osa, among age, neck circumference, body mass index, sex, pre/post menopausal status and pulmonary function tests parameters.

Eligibility criteria:
inclusion criteria: °patients planned for thyroidectomy for goiter exclusion criteria: * previous cervical surgery/radiotherapy * language barrier * chest disease known to narrow upper airways
efficacy and safety of insulin detemir versus neutral protamine hagedorn (nph) insulin in pregnant women with type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial is conducted in africa, europe, north and south america and oceania. the aim of this trial is to compare the effect and safety on blood glucose control in pregnant women with type 1 diabetes of a modern insulin analogue (insulin detemir) and human insulin (nph insulin) given as long-acting insulin in combination with a short-acting insulin (insulin aspart).


Eligibility criteria:
inclusion criteria: * type 1 diabetes treated with insulin for at least 12 months * planning to become pregnant and have a screening hba1c (glycosylated haemoglobin) lesser than or equal to 9.0%, or * pregnant with an intrauterine singleton living foetus, 8-12 weeks pregnant when joining the trial and a hba1c lesser than or equal to 8.0% when pregnancy is confirmed exclusion criteria: * known or suspected hypersensitivity to the trial product(s) or related products * untreated hyperthyroidism or hypothyroidism * known or suspected abuse of alcohol or narcotics * cardiac problems * impaired kidney function * history of severe hyperemesis gravidarum * treatment with in-vitro fertilisation or other medical infertility treatment * impaired liver function * uncontrolled hypertension * proliferative retinopathy or maculopathy requiring acute treatment * known to be hiv (human immunodeficiency virus) positive, hepatitis b or hepatitis c positive * any concomitant medication contraindicated in pregnancy
randomized clinical trial of intranasal injection of platelet-rich plasma for treatment of parosmia

Conditions: Paraosmia

Summary: this randomized clinical trial will evaluate the benefit of platelet-rich plasma (prp) in the treatment of qualitative olfactory dysfunction (parosmia). prp can be isolated from a patient's own blood and has been found in previous studies to have anti-inflammatory and pro-regenerative properties. it has been used across multiple specialties, such as orthopedics, facial plastics, dermatology, neurology in injected form to treat a wide variety of tissues to encourage the body's inherent regenerative capacity. the investigators have completed a randomized controlled trial here, ending in 2022, evaluating it's use in post-sars-cov-2 olfactory loss which demonstrated safety and efficacy. therefore, the investigators aim to assess the ability of prp to improve olfactory function in patients with parosmia.


Eligibility criteria:
inclusion criteria: * patients \>= 18 years of age * patients who have qualitative olfactory distortion * etiology of qualitative olfactory distortion is due to upper respiratory infection * quantitative score under the 10th percentile on the ssparot (hedrang and heddir) * quantitative score ≥ 8 on the qod. * at least 6 months of parosmia but less than 24 months * patients can have been previously treated with oral and topical steroids but this is not a requirement * patients will receive concurrent olfactory training - the practice of smelling strong odors (standard of care) * be able to read and understand english * be able and willing to provide informed consent exclusion criteria: * patients \< 18 years of age, pregnant females, patients who have structural abnormalities on nasal endoscopy or radiographic imaging that would prevent injection into the olfactory cleft * olfactory loss due to trauma, chronic sinusitis / inflammation / polyps, neoplasms, or neurodegenerative diseases or patients who have had olfactory loss \> 24 months * patients with bleeding disorders or on blood thinners such as coumadin and plavix
interaction of apelin and angiotensin in the human forearm circulation

Conditions: Heart Disease; Vasodilation

Summary: the apelin-apj system is a relatively new discovery. it has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease. apelin has the ability to cause blood vessels to relax, increasing their diameter and hence blood flow down the blood vessel. the researchers wish to investigate the hypothesis that an infusion of apelin will reduce the effects of angiotensin ii, which is know to reduce the diameter of blood vessels.


Eligibility criteria:
inclusion criteria: * \> 18 years old * healthy volunteers exclusion criteria: * lack of informed consent * age \< 18 years, * current involvement in other research studies, * systolic blood pressure \>190 mmhg or \<100 mmhg * malignant arrhythmias * renal or hepatic failure * haemodynamically significant aortic stenosis * severe or significant co morbidity * women of childbearing potential. * any regular medication * previous history of any cardiovascular disease

Keywords: renin angiotensin system apelin vasodilatation heart disease vascular biology
snmc (stronger neo-minophagen c ) for acute hepatitis post transarterial chemoembolization therapy

Conditions: Hepatocellular Carcinoma

Summary: a glycyrrhizin-containing product, stronger neo-minophagen c tm (snmc; minophagen pharmaceutical co.ltd.,tokyo,japan),is widely used in japan for suppression of hepatitis activity and for prevention of disease progression in patients with hepatitis b virus- and hcv-induced chronic hepatitis. in taiwan, snmc has been licensed by taiwan food and drug administration for the indication of maintain hepatic function. glycyrrhizin has been reported to mitigate hepatic inflammation by suppressing elevated alanine aminotransferase(alt) levels and preventing disease progression. the effect of snmc on acute deterioration of hepatic function following transarterial chemoembolization (tace) was still unknown. this study aimed to evaluate the effect of snmc on acute deterioration of hepatic function following tace.

hepatocellular carcinoma (hcc) is the fifth most common cancer in the world and the most common primary liver cancer. there are a variety of therapies for treatment of hcc; among them, transarterial chemoembolization (tace) is one of the most commonly used treatment modalities. tace induces ischemic tumor necrosis by obstruction of hepatic artery blood flow and exerts an anticancer effect via chemotherapeutic agents such as adriamycin or cisplatin mixed with lipiodol. in the american association for the study of liver diseases (aasld) guidelines for the management of hcc, tace is recommended for patients with intermediate-stage hcc according to the barcelona clinic liver cancer (bclc) staging system, because tace was found to improve survival compared with the best supportive care in patients with unresectable hcc. although tace is the established standard of care only for intermediate-stage hcc, in recent years, tace has been used widely even in treatment of advanced-stage hcc. the most frequent side effects of tace are fever, nausea, and abdominal pain, and these side effects are self-limiting in the majority of patients. however, acute deterioration of hepatic function following tace is a potentially life-threatening complication that occasionally interferes with continuation of tace in patients with hcc. although tace has marked direct antitumor effects, it can also result in more complications than conservative management, because the ischemic damage caused by tace can influence not only tumor tissue but non-tumorous liver tissue.this study aimed to evaluate the effect of snmc on acute deterioration of hepatic function following tace.

Eligibility criteria:
inclusion criteria: 1. intermediate-stage hcc according to the barcelona clinic liver cancer (bclc) staging system, either treatment naïve or experienced. 2. child's score belong to a or b(7) 3. total bilirubin level \<2 and prothrombin time prolong \<3" exclusion criteria: 1. had history of liver decompensation (ascites, encephalopathy, jaundice and varices bleeding) before this tace 2. has allergic history of snmc 3. consensus form cannot be available 4. hypokalemia (\<3.5 mmol/l)

Keywords: tace
first human dose trial for a new medication to potentially treat liver diseases

Conditions: Healthy Volunteers; Hepatic Steatosis

Summary: this study will assess the safety, tolerability, the pharmacokinetics from single injection (under the skin) of nnc0581-0001 and explores the pharmacodynamics in healthy participants and participants with hepatic steatosis (increased liver fat). participants will either get nnc0581-001 or placebo (dummy treatment). which treatment participants get is decided by chance.nnc0581-0001 is a new medicine which cannot be prescribed by doctors. the study will last about 58 weeks.


Eligibility criteria:
inclusion criteria, for healthy participants in part a: * female of non-childbearing potential or male aged 18-55 years (both inclusive) at the time of signing informed consent. * body mass index (bmi) from 18.5 to 30.0 kilogram per square meter (kg/m\^2) (both inclusive) at screening. * considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram, and clinical laboratory tests performed during the screening visit, as judged by the investigator. inclusion criteria for participants with hepatic steatosis in part b: * female of non-childbearing potential or male aged 18-55 years (both inclusive) at the time of signing informed consent. * body mass index (bmi) from 25.0 to 34.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening. * hepatic steatosis identified by a score above 248 db/m by fibroscan® (controlled attenuated parameter, cap) at screening. exclusion criteria * any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. * for part a: any laboratory safety parameters at screening outside the below laboratory ranges, see laboratory provided reference ranges for specific values (re-screening or re-sampling is not allowed if the participant has failed one of the exclusion criteria related to laboratory parameters): * alanine aminotransferase (alt) greater than upper normal limit (unl) plus 10 percent * aspartate aminotransferase (ast) greater than unl plus 10 percent * bilirubin greater than unl plus 10 percent * estimated glomerular filtration rate (egfr) below 90 milliliters per minute per 1.73 square meters (90 ml/min/1.73m\^2) * glycated haemoglobin (hba1c) greater than or equal to 5.7 percent (39 millimole per mole \[mmol/mol\]) at screening.
triclip ced rwe study

Conditions: Tricuspid Regurgitation

Summary: this coverage with evidence development (ced) study evaluates the long-term health outcomes of patients with symptomatic, severe or greater tricuspid regurgitation who received a tricuspid transcatheter edge-to-edge repair (t-teer) procedure using the triclip system.

the tricare will assess 2-year effectiveness in patients with symptomatic, severe or greater tr who undergo tricuspid transcatheter edge-to-edge repair (t-teer) with the triclip system, as compared to a contemporaneous control of patients without t-teer.

Eligibility criteria:
inclusion criteria: * patients ≥ 18 years of age at time of implant * patients with symptomatic, severe or greater tricuspid regurgitation who have received the triclip system (treatment group) or have not undergone t-teer (control group) exclusion criteria: * patients with less than severe tricuspid regurgitation * patients with a prior history of surgical or transcatheter tricuspid valve replacement * patients with a surgical or transcatheter aortic or mitral valve intervention prior to index

Keywords: triclip coverage with evidence development tricuspid transcatheter edge-to-edge repair